{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:33:43Z","timestamp":1772753623779,"version":"3.50.1"},"reference-count":84,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2011,6,2]],"date-time":"2011-06-02T00:00:00Z","timestamp":1306972800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0020643","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T11:48:46Z","timestamp":1307101726000},"page":"e20643","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":40,"title":["p53 Transactivation and the Impact of Mutations, Cofactors and Small Molecules Using a Simplified Yeast-Based Screening System"],"prefix":"10.1371","volume":"6","author":[{"given":"Virginia","family":"Andreotti","sequence":"first","affiliation":[]},{"given":"Yari","family":"Ciribilli","sequence":"additional","affiliation":[]},{"given":"Paola","family":"Monti","sequence":"additional","affiliation":[]},{"given":"Alessandra","family":"Bisio","sequence":"additional","affiliation":[]},{"given":"Mattia","family":"Lion","sequence":"additional","affiliation":[]},{"given":"Jennifer","family":"Jordan","sequence":"additional","affiliation":[]},{"given":"Gilberto","family":"Fronza","sequence":"additional","affiliation":[]},{"given":"Paola","family":"Menichini","sequence":"additional","affiliation":[]},{"given":"Michael A.","family":"Resnick","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Inga","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2011,6,2]]},"reference":[{"key":"ref1","first-page":"402","article-title":"Transcriptional control of human p53-regulated genes.","author":"T Riley","year":"2008"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nrc2730","article-title":"The expanding universe of p53 targets.","volume":"9","author":"D Menendez","year":"2009","journal-title":"Nature Rev Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"a000893","DOI":"10.1101\/cshperspect.a000893","article-title":"p53 Research: The Past Thirty Years and the Next Thirty Years.","volume":"2","author":"D Lane","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrc2715","article-title":"p53 and metabolism.","volume":"9","author":"KH Vousden","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"a001040","DOI":"10.1101\/cshperspect.a001040","article-title":"p53 regulation of metabolic pathways.","volume":"2","author":"E Gottlieb","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"a000968","DOI":"10.1101\/cshperspect.a000968","article-title":"The regulation of the p53-mediated stress response by MDM2 and MDM4.","volume":"2","author":"ME Perry","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use.","volume":"2","author":"M Olivier","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/ng1572","article-title":"Temporal dissection of p53 function in vitro and in vivo.","volume":"37","author":"MA Christophorou","year":"2005","journal-title":"Nat Genet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.cell.2007.02.022","article-title":"Wild-type p53: tumors can&apos;t stand it.","volume":"128","author":"MB Kastan","year":"2007","journal-title":"Cell"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbrc.2010.02.152","article-title":"The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer.","volume":"396","author":"M Farnebo","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature05529","article-title":"Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.","volume":"445","author":"W Xue","year":"2007","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature05541","article-title":"Restoration of p53 function leads to tumour regression in vivo.","volume":"445","author":"A Ventura","year":"2007","journal-title":"Nature"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6","article-title":"In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug.","volume":"67","author":"MV Blagosklonny","year":"1996","journal-title":"Int J Cancer"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1126\/science.286.5449.2507","article-title":"Pharmacological rescue of mutant p53 conformation and function [see comments].","volume":"286","author":"BA Foster","year":"1999","journal-title":"Science"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1126\/science.285.5434.1733","article-title":"A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy.","volume":"285","author":"PG Komarov","year":"1999","journal-title":"Science"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0959-437X(01)00264-7","article-title":"The p53 and Mdm2 families in cancer.","volume":"12","author":"D Michael","year":"2002","journal-title":"Curr Opin Genet Dev"},{"key":"ref17","first-page":"1476","article-title":"MDM2 and MDM4: p53 regulators as targets in anticancer therapy.","author":"F Toledo","year":"2007"},{"key":"ref18","first-page":"909","article-title":"Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.","author":"F Toledo","year":"2006"},{"key":"ref19","first-page":"11300","article-title":"The conserved CPH domains of Cul7 and PARC are protein-protein interaction modules that bind the tetramerization domain of p53.","author":"L Kaustov","year":"2007"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/378203a0","article-title":"Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.","volume":"378","author":"R Montes de Oca Luna","year":"1995","journal-title":"Nature"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccr.2009.02.004","article-title":"p53 and MDM2: antagonists or partners in crime?","volume":"15","author":"CM Eischen","year":"2009","journal-title":"Cancer Cell"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/modpathol.3800727","article-title":"HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target.","volume":"20","author":"X Han","year":"2007","journal-title":"Mod Pathol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.humpath.2007.03.005","article-title":"High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.","volume":"38","author":"YA Valentin-Vega","year":"2007","journal-title":"Hum Pathol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrd1343","article-title":"Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.","volume":"3","author":"MR Arkin","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm1146","article-title":"Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.","volume":"10","author":"N Issaeva","year":"2004","journal-title":"Nat Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.","volume":"303","author":"LT Vassilev","year":"2004","journal-title":"Science"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"845","DOI":"10.4161\/cbt.7.6.5841","article-title":"A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy.","volume":"7","author":"SH Sun","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.4161\/cc.6365","article-title":"Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.","volume":"7","author":"GM Popowicz","year":"2008","journal-title":"Cell Cycle"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-08-0140","article-title":"Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.","volume":"7","author":"S Shangary","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"9934","DOI":"10.1073\/pnas.1633803100","article-title":"Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity.","volume":"100","author":"MA Resnick","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e1000104","DOI":"10.1371\/journal.pgen.1000104","article-title":"Noncanonical DNA motifs as transactivation targets by wild type and mutant p53.","volume":"4","author":"JJ Jordan","year":"2008","journal-title":"PLoS Genet"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1073\/pnas.0501721102","article-title":"Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation.","volume":"102","author":"DJ Tomso","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1073\/pnas.0704694105","article-title":"Functional evolution of the p53 regulatory network through its target response elements.","volume":"105","author":"AG Jegga","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nm0697-632","article-title":"Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain.","volume":"3","author":"G Selivanova","year":"1997","journal-title":"Nat Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm0302-282","article-title":"Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.","volume":"8","author":"VJ Bykov","year":"2002","journal-title":"Nat Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1038\/onc.2010.188","article-title":"Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.","volume":"29","author":"KG Wiman","year":"2010","journal-title":"Oncogene"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1126\/science.285.5434.1733","article-title":"A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.","volume":"285","author":"PG Komarov","year":"1999","journal-title":"Science"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"8612","DOI":"10.1128\/MCB.22.24.8612-8625.2002","article-title":"Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence.","volume":"22","author":"A Inga","year":"2002","journal-title":"Mol Cell Biol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1124\/mol.107.044651","article-title":"Enhancing drug accumulation in Saccharomyces cerevisiae by repression of pleiotropic drug resistance genes with chimeric transcription repressors.","volume":"74","author":"A Stepanov","year":"2008","journal-title":"Mol Pharmacol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0076-6879(05)09019-1","article-title":"The delitto perfetto approach to in vivo site-directed mutagenesis and chromosome rearrangements with synthetic oligonucleotides in yeast.","volume":"409","author":"F Storici","year":"2006","journal-title":"Methods Enzymol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"14994","DOI":"10.1073\/pnas.2036296100","article-title":"Chromosomal site-specific double-strand breaks are efficiently targeted for repair by oligonucleotides in yeast.","volume":"100","author":"F Storici","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/0092-8674(86)90349-1","article-title":"Double-strand breaks can initiate meiotic recombination in S. cerevisiae.","volume":"46","author":"AL Kolodkin","year":"1986","journal-title":"Cell"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1128\/MCB.17.5.2859","article-title":"Hypermutability of homonucleotide runs in mismatch repair and DNA polymerase proofreading yeast mutants.","volume":"17","author":"HT Tran","year":"1997","journal-title":"Mol Cell Biol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/BF00351651","article-title":"Interaction of the yeast pleiotropic drug resistance genes PDR1 and PDR5.","volume":"21","author":"S Meyers","year":"1992","journal-title":"Curr Genet"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/hmg\/ddp305","article-title":"A functional genetic study identifies HAND1 mutations in septation defects of the human heart.","volume":"18","author":"SM Reamon-Buettner","year":"2009","journal-title":"Hum Mol Genet"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1073\/pnas.92.9.3963","article-title":"A simple p53 functional assay for screening cell lines, blood, and tumors.","volume":"92","author":"JM Flaman","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.onc.1204116","article-title":"p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.","volume":"20","author":"A Inga","year":"2001","journal-title":"Oncogene"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1074\/jbc.M210908200","article-title":"Studies with novel Pdr5p substrates demonstrate a strong size dependence for xenobiotic efflux.","volume":"278","author":"J Golin","year":"2003","journal-title":"J Biol Chem"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1128\/AEM.69.2.805-811.2003","article-title":"A sensitive and inexpensive yeast bioassay for the mycotoxin zearalenone and other compounds with estrogenic activity.","volume":"69","author":"R Mitterbauer","year":"2003","journal-title":"Appl Environ Microbiol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s000180050273","article-title":"Functions of the MDM2 oncoprotein.","volume":"55","author":"DA Freedman","year":"1999","journal-title":"Cell Mol Life Sci"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.1093\/emboj\/20.22.6404","article-title":"hADA3 is required for p53 activity.","volume":"20","author":"T Wang","year":"2001","journal-title":"Embo J"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/carcin\/23.4.541","article-title":"p53-Mdm2\u2014the affair that never ends.","volume":"23","author":"D Alarcon-Vargas","year":"2002","journal-title":"Carcinogenesis"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"11936","DOI":"10.1073\/pnas.220252297","article-title":"Phosphorylation of murine p53 at ser-18 regulates the p53 responses to DNA damage.","volume":"97","author":"C Chao","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1093\/emboj\/18.24.7002","article-title":"Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2.","volume":"18","author":"N Dumaz","year":"1999","journal-title":"Embo J"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1091\/mbc.11.12.4241","article-title":"Genomic expression programs in the response of yeast cells to environmental changes.","volume":"11","author":"AP Gasch","year":"2000","journal-title":"Mol Biol Cell"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"e1507","DOI":"10.1371\/journal.pone.0001507","article-title":"Reconstitution of Mdm2-dependent post-translational modifications of p53 in yeast.","volume":"3","author":"B Di Ventura","year":"2008","journal-title":"PLoS One"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1128\/MCB.23.7.2556-2563.2003","article-title":"p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice.","volume":"23","author":"IM Ward","year":"2003","journal-title":"Mol Cell Biol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"6098","DOI":"10.1073\/pnas.91.13.6098","article-title":"Two cellular proteins that bind to wild-type but not mutant p53.","volume":"91","author":"K Iwabuchi","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.semcancer.2010.02.006","article-title":"Therapeutic targeting of p53 by small molecules.","volume":"20","author":"G Selivanova","year":"2010","journal-title":"Semin Cancer Biol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ccr.2009.03.021","article-title":"Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis.","volume":"15","author":"VV Grinkevich","year":"2009","journal-title":"Cancer Cell"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ccr.2009.03.003","article-title":"PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.","volume":"15","author":"JM Lambert","year":"2009","journal-title":"Cancer Cell"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/nsmb.1872","article-title":"The C terminus of p53 binds the N-terminal domain of MDM2.","volume":"17","author":"MV Poyurovsky","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1126\/science.274.5289.948","article-title":"Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.","volume":"274","author":"PH Kussie","year":"1996","journal-title":"Science"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1042\/BST0370897","article-title":"53BP1: function and mechanisms of focal recruitment.","volume":"37","author":"JE FitzGerald","year":"2009","journal-title":"Biochem Soc Trans"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1128\/MCB.01644-09","article-title":"Role of ATM and the damage response mediator proteins 53BP1 and MDC1 in the maintenance of G(2)\/M checkpoint arrest.","volume":"30","author":"A Shibata","year":"2010","journal-title":"Mol Cell Biol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.molcel.2009.06.037","article-title":"A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency.","volume":"35","author":"L Cao","year":"2009","journal-title":"Mol Cell"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1093\/emboj\/cdf383","article-title":"Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor.","volume":"21","author":"DJ Derbyshire","year":"2002","journal-title":"Embo J"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"34660","DOI":"10.1074\/jbc.M806020200","article-title":"Role for 53BP1 Tudor domain recognition of p53 dimethylated at lysine 382 in DNA damage signaling.","volume":"283","author":"I Kachirskaia","year":"2008","journal-title":"J Biol Chem"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jmb.2010.03.024","article-title":"Structural insight into p53 recognition by the 53BP1 tandem Tudor domain.","volume":"398","author":"S Roy","year":"2010","journal-title":"J Mol Biol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/0008-5472.CAN-06-2710","article-title":"Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2.","volume":"67","author":"GA LaRusch","year":"2007","journal-title":"Cancer Res"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/carcin\/23.12.2011","article-title":"Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database.","volume":"23","author":"VJ Bykov","year":"2002","journal-title":"Carcinogenesis"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"R765","DOI":"10.1186\/bcr1290","article-title":"Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells.","volume":"7","author":"A Rehman","year":"2005","journal-title":"Breast Cancer Res"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbrc.2010.10.031","article-title":"PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells.","volume":"402","author":"D Russo","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.","volume":"463","author":"J Zhang","year":"2010","journal-title":"Nature"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1158\/0008-5472.CAN-09-0337","article-title":"HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.","volume":"69","author":"C Rinaldo","year":"2009","journal-title":"Cancer Res"},{"key":"ref76","article-title":"Distinct regulation of p53-mediated apoptosis by protein kinase Calpha, delta, epsilon and zeta: Evidence in yeast for transcription-dependent and -independent p53 apoptotic mechanisms.","author":"I Coutinho","year":"2011"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.febslet.2009.10.030","article-title":"Differential regulation of p53 function by protein kinase C isoforms revealed by a yeast cell system.","volume":"583","author":"I Coutinho","year":"2009","journal-title":"FEBS Lett"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1038\/sj.onc.1204457","article-title":"Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.","volume":"20","author":"A Inga","year":"2001","journal-title":"Oncogene"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1038\/sj.onc.1210302","article-title":"TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.","volume":"26","author":"A Petitjean","year":"2007","journal-title":"Oncogene"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"14338","DOI":"10.1073\/pnas.94.26.14338","article-title":"Thermodynamic stability of wild-type and mutant p53 core domain.","volume":"94","author":"AN Bullock","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"8424","DOI":"10.1073\/pnas.1431692100","article-title":"Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.","volume":"100","author":"S Kato","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"12231","DOI":"10.1073\/pnas.0705319104","article-title":"Quaternary structure of p53: the light at the end of the tunnel.","volume":"104","author":"Z Shakked","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.molcel.2006.05.015","article-title":"Structural basis of DNA recognition by p53 tetramers.","volume":"22","author":"M Kitayner","year":"2006","journal-title":"Mol Cell"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nsmb.1800","article-title":"Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs.","volume":"17","author":"M Kitayner","year":"2010","journal-title":"Nat Struct Mol Biol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0020643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T09:22:39Z","timestamp":1589016159000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0020643"}},"subtitle":[],"editor":[{"given":"Janine","family":"Santos","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2011,6,2]]},"references-count":84,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,6,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0020643","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,2]]}}}